共 50 条
- [31] Systemic CD4 Immunity and PD-L1/PD-1 Blockade ImmunotherapyINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (21)Escors, DavidBocanegra, AnaChocarro, LuisaBlanco, EsterPineiro-Hermida, SergioGarnica, MaiderFernandez-Rubio, LeticiaVera, RuthArasanz, HugoKochan, Grazyna
- [32] Mitoxantrone in combination with TGFß and PD-1 blockade remodels the tumor immune landscape enhancing neuroblastoma antitumor immunityCANCER RESEARCH, 2022, 82 (12)Lucarini, ValeriaMelaiu, OmbrettaD'Amico, SilviaPastorino, FabioTempora, PatriziaDe Ninno, AdeleBusinaro, LucaPonzoni, MircoLocatelli, FrancoFruci, Doriana
- [33] PD-1 BLOCKADE ADMINISTERED BEFORE OR AT THE TIME OF T CELL ACTIVATION ENHANCES ANTI-TUMOR IMMUNITYJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A492 - A492Moseman, JenaMcNeel, Douglas
- [34] Anti-tumor immunity evolved by novel titanium peroxide nanoparticles (TiOxNPs) as a radiosensitizer and PD-1 blockadeCANCER RESEARCH, 2023, 83 (07)Fujita, YoshikoKubota, HikaruOgino, ChiakiSasaki, Ryohei
- [35] Cutting Edge: Targeting Thrombocytes to Rewire Anticancer Immunity in the Tumor Microenvironment and Potentiate Efficacy of PD-1 BlockadeJOURNAL OF IMMUNOLOGY, 2019, 203 (05): : 1105 - 1110Riesenberg, Brian P.Ansa-Addo, Ephraim A.Gutierrez, JenniferTimmers, Cynthia D.Liu, BeiLi, Zihai
- [36] The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor ImmunityCANCER IMMUNOLOGY RESEARCH, 2019, 7 (09) : 1457 - 1471Palakurthi, SangeethaKuraguchi, MariZacharek, Sima J.Zudaire, EnriqueHuang, WeiBonal, Dennis M.Liu, JeffreyDhaneshwar, AbhaDePeaux, KristinGowaski, Martha R.Bailey, DyaneRegan, Samuel N.Ivanova, ElenaFerrante, CatherineEnglish, Jessie M.Khosla, AdityaBeck, Andrew H.Rytlewski, Julie A.Sanders, CatherineLaquerre, SylvieBittinger, Mark A.Kirschmeier, Paul T.Packman, KathrynJanne, Pasi A.Moy, ChristopherWong, Kwok-KinVerona, Raluca I.Lorenzi, Matthew V.
- [37] Soluble forms of the immune check-point receptor PD-1 and its ligand PD-L1 in blood serum of patients with renal cell carcinoma: clinical and pathologic correlationsONKOUROLOGIYA, 2019, 15 (01): : 15 - 22Kushlinskii, N. E.Gershtein, E. S.Goryatcheva, I. O.Morozov, A. A.Alferov, A. A.Bezhanova, S. D.Kazantseva, I. A.Bazaev, V. V.Matveev, V. B.
- [38] Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockadeJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5Lipson, Evan J.Lilo, Mohammed T.Ogurtsova, AleksandraEsandrio, JessicaXu, HaiyingBrothers, PatriciaSchollenberger, MeganSharfman, William H.Taube, Janis M.
- [39] Chemoimmunotherapy with PD-1 blockade and paclitaxel induce a potent antitumor immunity in ovarianCLINICAL CANCER RESEARCH, 2016, 22Hamanishi, JunzoPeng, JinMatsumura, NoriomiAbiko, KaoruBaba, TsukasaYamaguchi, KenKonishi, IkuoMandai, Masaki
- [40] PD-1 blockade enhances elotuzumab efficacy in mouse tumor modelsBLOOD ADVANCES, 2017, 1 (12) : 753 - 765Bezman, Natalie A.Jhatakia, AmyKearney, Alper Y.Brender, TyMaurer, MarkHenning, KarlaJenkins, Misty R.Rogers, Amy J.Neeson, Paul J.Korman, Alan J.Robbins, Michael D.Graziano, Robert F.